Skip to main content
. 2018 Apr 5;20(8):1034–1043. doi: 10.1093/neuonc/noy027

Table 2.

Phase II primary endpoints

RCT Non-RCT Total
Progression-free survival 13 (8%) 85 (51%) 98 (59%)
Overall survival 11 (7%) 34 (20%) 45 (27%)
Safety/toxicity/MTD 7 (4%) 19 (11%) 26 (16%)
Imaging/response 3 (2%) 28 (17%) 31 (19%)
PK/PD 2 (1%) 5 (3%) 7 (4%)
Other 4 (2%) 4 (2%)
Total 25 (15%) 141 (85%) 166 (100%)